Sign In
Buy TEM
$50.56
-1.76 (-3.36%)
At Close: Jun 16, 2026
Tempus AI, Inc. (TEM) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
05:21pm, Tuesday, 14'th Apr 2026
Tempus AI, Inc. (TEM) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Tempus AI Stock Jumps As Data Presentations Fuel Fresh AI Oncology Buzz
02:29pm, Tuesday, 14'th Apr 2026
Tempus AI (NASDAQ:TEM) shares are up on Tuesday as the company announced the acceptance of 31 abstracts for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026.
Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026
08:30am, Tuesday, 14'th Apr 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acceptance of 31 abstracts—including one o
Tempus Launches Automated “Active Follow-Up” Service to Support Guideline-Concordant Care
08:30am, Monday, 13'th Apr 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of an automated clinical update servi
Pre-Market Stock Futures: Futures are trading lower this morning after negotiations with Iran failed over the weekend, and President Trump indicated the U.S. will block the Strait of Hormuz. This come
TEM Stock Gains 17.9% in a Year: Time to Buy, Hold or Sell?
01:06pm, Thursday, 09'th Apr 2026
Tempus AI rides on diagnostics growth, AI-driven data demand, and pricing gains - but persistent losses and valuation questions complicate the buy-or-sell call.
Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE
08:30am, Thursday, 09'th Apr 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced an expanded, multi-year collaboration with Gilea
Tempus to Present at the 25th Annual Needham Virtual Healthcare Conference
04:01pm, Wednesday, 08'th Apr 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, will present at the 25th Annual Needham Virtual Healthcare Confe
What's Driving TEM Data and Applications Arm's Robust Growth?
03:26pm, Tuesday, 07'th Apr 2026
Tempus AI's data arm surges with 69.5% Insights growth, $1.1B+ contracts, and AI-driven expansion fueling strong revenue outlook and customer retention gains.
Tempus AI, Inc. $TEM Shares Bought by Aberdeen Group plc
03:09am, Tuesday, 07'th Apr 2026
Aberdeen Group plc grew its holdings in shares of Tempus AI, Inc. (NASDAQ: TEM) by 64.2% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commissi
Step Capital Management Pte. Ltd. Makes New Investment in Tempus AI, Inc. $TEM
07:00am, Monday, 06'th Apr 2026
Step Capital Management Pte. Ltd. purchased a new position in shares of Tempus AI, Inc. (NASDAQ: TEM) in the undefined quarter, according to the company in its most recent filing with the SEC. The ins
Alternate Health (OTCMKTS:AHGIF) & Tempus AI (NASDAQ:TEM) Head-To-Head Review
01:55am, Sunday, 05'th Apr 2026
Tempus AI (NASDAQ: TEM - Get Free Report) and Alternate Health (OTCMKTS:AHGIF - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses ba
Tempus AI: A Dual-Engine AI Model
08:25am, Friday, 03'rd Apr 2026
Tempus AI is a diagnostics and data platform leveraging a large healthcare dataset to inform clinical decision-making. Strong 2025 performance driven by diagnostics growth, oncology re-acceleration, a
Tempus AI Stock Gains Following the ALERT Trial Result Announcement
03:01pm, Thursday, 02'nd Apr 2026
TEM jumps after ALERT trial shows EHR alerts boost timely valve care, improving evaluations and interventions for aortic stenosis and MR patients.
What's Fueling TEM Diagnostics Segment's Strong 2026 Outlook?
11:26am, Wednesday, 01'st Apr 2026
TEM's diagnostics arm surges on oncology demand, MRD adoption and rising pricing, with 2026 growth set to stay strong as sequencing and reimbursement expand.
